GC Labcell said that it has published a paper related to genetically engineered support cells, one of its culture platform technologies, in the latest issue of Cellular & Molecular Immunology.

GC Labcell has published its study on NK cell mass culture core technology in an international medical journal.
GC Labcell has published its study on NK cell mass culture core technology in an international medical journal.

“This paper is about a unique technology for support cells that induce proliferation and activity of natural killer (NK) cells, which is the key to mass production of cell therapy products,” the company said. “The GC Labcell research team scientifically proved the principle of using T cells as support cells for NK cell culture.”

Using this, the company developed a genetically engineered feeder that allows the expression of co-stimulatory factors (4-1BBL, TNF-α, IL-21) as a cell membrane-binding protein. According to the company, this unique support cell technology is the core of GC Labcell culture technology that can mass-produce NK cells with near 100% purity in a short period.

Global companies and academia have recognized GC Labcell’s technology for producing cell therapy products with high productivity, economy, and safety.

The company added that clinical trials for an NK cell therapy based on the technology are already underway in the U.S.

Copyright © KBR Unauthorized reproduction, redistribution prohibited